Hematoporphyrin photoradiation therapy for intraocular and orbital malignant melanoma.
Photoradiation therapy (PRT) is a new technique that is currently under investigation for the treatment of a variety of solid malignant tumors. The technique involves systemic administration of hematoporphyrin derivative (HpD), a photosensitizing compound that is preferentially retained by malignant cells and photoactivation of the neoplasm with red light (630 nm) to achieve selective destruction of cancer cells. We used HpD PRT for seven patients with malignant melanoma of the uvea and conclude that initial results of HpD PRT for uveal malignant melanoma are encouraging and justify further investigation.
D005134:Eye Neoplasms / Q000188:drug therapy*; D005260:Female; D017324:Hematoporphyrin Derivative; D006415:Hematoporphyrins / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D009918:Orbital Neoplasms / Q000188:drug therapy*; D010778:Photochemotherapy / Q000009:adverse effects; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D014978:Xenon / Q000627:therapeutic use
D006415:Hematoporphyrins; D011838:Radiation-Sensitizing Agents; D014978:Xenon; D017324:Hematoporphyrin Derivative